PE-22-28

Nootropic / Mood

Antidepressant and neuroplasticity positioning

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Peptide
Primary mechanism: Spadin-related TREK-1 modulation
Primary market use: Mood/cognition

Pharmacology

Molecular weight (Da): ~1000
Oral bioavailability: N/A
Half-life: ~5–60 min parent peptide; analogs may be longer
Route tags: SubQ; Injectable; route-dependent
Evidence level: Preclinical
Clinical status: Experimental
Value-for-money score: 4 / 10

Reported protocol signal

Intranasal: • 400 mcg daily in the morning (Jay Campbell)

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

Experimental peptide

Sources

https://pubmed.ncbi.nlm.nih.gov/